Array BioPharma Inc
Amarin’s Q2 Earnings and Robust 2019 Outlook
Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.
How PFE’s and BMY’s EPS Trends Compare
In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.
An Overview of Array BioPharma Stock
Array BioPharma generated total revenue of $56.91 million in the first quarter of fiscal 2019.
How Analysts View Amicus Therapeutics in September
Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.
NovoCure Stock Rose after Positive Results from Clinical Trial
On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40.
What Analysts Recommend for Array BioPharma Stock
As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.
Array BioPharma Missed Sales Estimates for Q4 2018
Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.
Gauging Analysts’ Ratings for ArQule Stock in July
ArQule (ARQL) stock has risen from a low of $5.53 on July 5 to $6.86 on July 6. It closed 20.11% higher at $6.81 on July 6.
Array BioPharma: Why Wall Street Analysts Are Positive
Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”
Array BioPharma’s Financial Performance
The total revenues of Array BioPharma (ARRY) decreased from $39.2 million in 1Q17 to $29.7 million in 1Q18.
Array BioPharma’s ARRY-382 and ARRY-797
Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.
Array BioPharma’s Promising Drug for Colorectal Cancer
On January 22, 2018, Array BioPharma announced data from the BEACON CRC trial, which showed a median progression-survival rate of eight months and an overall response rate of 48%.
An In-Depth Look at Array BioPharma’s Pipeline of Drugs
In March 2015, Array BioPharma (ARRY) got the development and commercialization rights for binimetinib and encorafenib under asset transfer agreements with Novartis (NVS).
Analyst Ratings for Array BioPharma and Peers in January 2018
Of the nine analysts covering Array BioPharma (ARRY) in January 2018, eight have given the stock a “buy” or higher rating, and one has given it a “hold.”
Taking Stock of Radius Health’s Financial Performance
In 3Q17, Radius Health (RDUS) generated revenue of $13.4 million. Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue.
Taking Stock of Radius Health’s Licensing Agreements
The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.
Analysts’ Ratings for Radius Health and Its Peers in January
In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.